GlassScriptPhysician profile
Sergio Infante
NPI 1962611897
$9,179.35
in general payments reported to CMS, 2019-2025
17 companies · $6,019 in 2025
The $6,019 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $49.85 · 2021: $41.27 · 2022: $125 · 2023: $269 · 2024: $2,005 · 2025: $6,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,214 · Food and Beverage: $2,470 · Travel and Lodging: $1,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,213.60 |
| Food and Beverage | $2,470.32 |
| Travel and Lodging | $1,609.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $5,300.37 | 2025 | Renal - Acute |
| Baxter Healthcare | $1,314.33 | 2019-2024 | Renal - Acute |
| Mallinckrodt Hospital Products INC. | $544.63 | 2024-2025 | Terlivaz, Acthar |
| Akebia Therapeutics INC | $374.76 | 2019-2025 | Vafseo |
| Astrazeneca Pharmaceuticals LP | $249.99 | 2019-2023 | Lokelma |
| Ardelyx, INC. | $249.83 | 2024 | Xphozah 30 Mg |
| Fresenius USA Marketing, INC. | $140.63 | 2019-2021 | |
| Calliditas Therapeutics US INC. | $140.49 | 2023-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $130.50 | 2023 | Lupkynis |
| Apellis Pharmaceuticals, INC. | $125.00 | 2025 | Empaveli |
| Genzyme Corporation | $124.99 | 2024 | |
| Glaxosmithkline, LLC. | $124.99 | 2025 | Benlysta |
| Amgen INC. | $124.98 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $79.79 | 2019 | |
| Novo Nordisk INC | $77.55 | 2025 | Rivfloza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $61.75 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $14.77 | 2025 | Rayaldee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Infante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.